Drug analysis: Lonsurf

  • ID: 4462196
  • Drug Pipelines
  • 18 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Lonsurf ([trifluridine + tipiracil]; Otsuka/Servier) is an oral combination drug with both anti-angiogenic and cytotoxic effects. It is composed of trifluridine, an antineoplastic nucleoside analog, and tipiracil hydrochloride, a thymidine phosphorylase inhibitor. Following uptake into the cancer cells, trifluridine is incorporated into DNA, thereby interfering with DNA synthesis and inhibiting cell proliferation. Tipiracil hydrochloride increases the bioavailability of trifluridine by preventing its rapid metabolism and ensuring the blood concentration of trifluridine is maintained.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Lonsurf: Colorectal cancer (CRC)

List of Figures
Figure 1: Lonsurf for colorectal cancer - SWOT analysis
Figure 2: Drug assessment summary of Lonsurf for colorectal cancer
Figure 3: Drug assessment summary of Lonsurf for colorectal cancer
Figure 4: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25

List of Tables
Table 1: Lonsurf drug profile
Table 2: Lonsurf Phase III data in colorectal cancer
Table 3: Lonsurf Phase II trials in colorectal cancer
Table 4: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 5: Patients treated with Lonsurf across the US, Japan, and five major EU markets, by country, 2016-25
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll